The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Association of KMT2C loss-of-function mutations in circulating tumor DNA and prolonged response to the combination of PARPi and PI3Ki.
 
Felipe Batalini
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; GRAIL
Speakers' Bureau - GRAIL
Research Funding - Caris Life Sciences (Inst); Foundation Medicine (Inst); Invitae (Inst)
 
Shizong Ke
No Relationships to Disclose
 
Ruolin Liu
No Relationships to Disclose
 
Tim Blewett
No Relationships to Disclose
 
Justin Rhoades
No Relationships to Disclose
 
Doga Gulhan
No Relationships to Disclose
 
Panagiotis A. Konstantinopoulos
Consulting or Advisory Role - AADi; Alkermes; Artios; AstraZeneca; Bayer; Kadmon; Merck; Mersana; Novartis; Pfizer/EMD Serono; Repare Therapeutics; Tesaro; Vertex
Research Funding - AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb/Sanofi (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); tesaro (Inst)
 
Ursula A. Matulonis
Honoraria - Advaxis; Alkermes; Symphogen
Consulting or Advisory Role - 2X Oncology; Agenus; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; GlaxoSmithKline; Immunogen; Merck; NextCure; Novartis; Trillium Therapeutics
Research Funding - Fujifilm; Immunogen; Leap Therapeutics; Merck; Mersana; Novartis; SQZ Biotech; Syndax; Tesaro
Travel, Accommodations, Expenses - AstraZeneca
 
Viktor Adalsteinsson
Honoraria - Danaher
Patents, Royalties, Other Intellectual Property - Patents on cell-free DNA sequencing methods filed by the Broad Institute.
 
Gerburg M. Wulf
Stock and Other Ownership Interests - Selecta Biosciences (I)
Research Funding - GlaxoSmithKline (Inst); Merck
Patents, Royalties, Other Intellectual Property - Pin1 as a marker for abnormal cell growth Patent number: 8129131; Pin1 inhibitors (Inst)